Stock Information
symbol line chart

INBSIntelligent Bio Solutions Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Harry Simeonidis

Location

New York, USA

Exchange

Nasdaq

Website

https://gbs.inc

Summary

GBS Inc.

Company Info

CEO

Harry Simeonidis

Location

New York, USA

Exchange

Nasdaq

Website

https://gbs.inc

Summary

GBS Inc.

AI Insights for INBS
4 min read

Quick Summary

Intelligent Bio Solutions Inc. is a small medical technology and biosensor diagnostics company focused on non-invasive testing solutions. The company is associated with biosensor platforms that aim to collect biological information without relying on more invasive blood draws or traditional laboratory workflows. Its current public focus is the Intelligent Fingerprinting Drug Screening System, which uses sweat collected from fingertips to test for commonly abused drugs. The company’s target customers include employers, safety-critical industries, drug rehabilitation providers, law enforcement, forensic users, and other organizations that need fast screening results. INBS is very small, with about 10 employees and roughly $4.2 million in reported operating revenue, so its commercial progress is highly dependent on regulatory approvals, customer adoption, and successful market expansion.

Strengths

•

INBS’s main strength is its differentiated non-invasive testing approach using fingerprint sweat.

•

The Intelligent Fingerprinting platform offers rapid results in under 10 minutes, which could be attractive in workplace and safety-critical environments.

•

The company’s technology may reduce the discomfort, privacy issues, and logistical complexity associated with traditional urine or blood-based testing.

•

Its FDA submission provides a tangible regulatory milestone that may increase credibility if the review progresses favorably.

•

The company also operates in drug screening markets where speed, convenience, compliance, and cost reduction are meaningful customer priorities.

Key Risks

•

The biggest risk is that the FDA may delay, question, or reject the 510(k) submission, which would materially harm the U.S. commercialization plan.

•

Even if clearance is obtained, customers may be slow to adopt a newer fingerprint sweat testing method if they prefer established urine, saliva, hair, or laboratory-based testing.

•

INBS’s financial losses raise the risk of future share dilution, debt financing, or liquidity pressure.

•

The company’s high beta and micro-cap status make the stock vulnerable to sharp price swings unrelated to fundamental progress.

What to Watch

During the most recent reported period, the company remained a very small, loss-making diagnostics business with operating revenue of about $4.2 million and net income of approximately negative $12.5 million.
The most important recent corporate event was the submission of a 510(k) premarket notification to the U.S.
FDA for the Intelligent Fingerprinting Drug Screening System.
The submission included validation and performance data, including a method comparison study showing 94.1% accuracy.
The company also highlighted pharmacokinetic study results indicating that fingerprint sweat can be a reliable sample type for drug detection.
This regulatory filing represents a major step toward the company’s planned entry into the U.S. market in 2025.

Price Drivers

•

INBS’s stock price is likely driven mainly by regulatory milestones, especially the FDA 510(k) submission and any future clearance decision for the Intelligent Fingerprinting Drug Screening System.

•

Because the company is small and currently unprofitable, investor sentiment can change sharply based on perceived commercialization prospects rather than current earnings.

•

The stock has a very high beta of 4.302, which suggests it may move much more aggressively than the broader market.

•

Its 52-week range from $1.52 to $24.90 indicates extreme volatility and sensitivity to news, financing concerns, and speculative trading.

•

Other drivers include revenue growth, cash runway, potential dilution, partnership announcements, customer wins, and broader risk appetite for micro-cap medical technology stocks.

Recent News

•

INBS recently announced that it submitted a 510(k) premarket notification to the U.S.

•

FDA for its Intelligent Fingerprinting Drug Screening System.

•

The system uses sweat collected from fingertips to detect commonly abused workplace drugs.

•

The filing included validation and performance data, including a reported 94.1% accuracy result from a method comparison study.

•

The company also cited a pharmacokinetic study suggesting that fingerprint sweat results aligned closely with blood-based data at a 95% confidence level.

•

CEO Harry Simeonidis described the submission as an important milestone as the company works toward U.S. market entry and broader commercial expansion.

Market Trends

•

The drug testing market is being shaped by demand for faster, less invasive, and easier-to-administer screening methods.

•

Employers in safety-sensitive industries continue to need testing solutions that balance compliance, speed, cost, and employee experience.

•

Cannabis legalization and changing workplace drug policies create both complexity and opportunity for testing providers.

•

Point-of-care and decentralized diagnostics are gaining attention because they can reduce turnaround times and operational friction.

•

At the same time, regulators, employers, and courts often require strong validation, reliability, and defensibility, which means new testing technologies must overcome high trust and compliance barriers.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on INBS

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show